Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) EBITDA (2017 - 2025)

Selectis Health's EBITDA history spans 14 years, with the latest figure at $67739.0 for Q3 2025.

  • For Q3 2025, EBITDA rose 108.49% year-over-year to $67739.0; the TTM value through Sep 2025 reached -$175795.0, up 95.59%, while the annual FY2024 figure was -$2.7 million, 62.58% up from the prior year.
  • EBITDA for Q3 2025 was $67739.0 at Selectis Health, up from -$87547.0 in the prior quarter.
  • Across five years, EBITDA topped out at $1.8 million in Q2 2022 and bottomed at -$2.6 million in Q4 2023.
  • The 5-year median for EBITDA is -$272665.0 (2024), against an average of -$336004.3.
  • The largest annual shift saw EBITDA skyrocketed 85648.96% in 2022 before it plummeted 508.27% in 2023.
  • A 5-year view of EBITDA shows it stood at -$715292.0 in 2021, then tumbled by 38.18% to -$988381.0 in 2022, then crashed by 159.27% to -$2.6 million in 2023, then surged by 96.2% to -$97261.0 in 2024, then soared by 169.65% to $67739.0 in 2025.
  • Per Business Quant, the three most recent readings for GBCS's EBITDA are $67739.0 (Q3 2025), -$87547.0 (Q2 2025), and -$58726.0 (Q1 2025).